What are the opening hours?

Monday 9am - 6pm Tuesday 9am - 6pm Wednesday 9am - 6pm Thursday 9am - 6pm Friday 9am - 6pm

Granules India Limited

Home
India
Hyderabad
Granules India Limited

Granules India Limited is generic pharmaceutical company headquartered in Hyderabad, India.

09/01/2026

As part of our CSR initiative ‘Avoidable Blindness-free Schools’, Granules India Limited screened over 3,000 students across 23 government schools in Gummadidala Mandal, Sangareddy district, through L V PRASAD EYE INSTITUTE

Today, spectacles were distributed to students identified with vision challenges at Bonthapally Zila Parishad High School, in the presence of Mrs. Uma Chigurupati, Executive Director at Granules India Limited, and local education authorities.

Speaking at the event, she reaffirmed the company’s commitment to community well-being and said, “Eye health is fundamental to a child’s learning journey. Granules will continue to support initiatives that help students from underserved backgrounds to improve their learning outcomes at school.”

08/01/2026

We are pleased to share that Granules Pharmaceuticals, Inc., our wholly-owned subsidiary, has received Tentative Approval from the USFDA for its ANDA for generic Amphetamine Extended-Release Tablets (5 mg, 10 mg, 15 mg, 20 mg), the generic equivalent of DYANAVEL XR®.

The product is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), and we are eligible for 180-day exclusivity.

This marks the second approval from our US-based subsidiary within a few weeks, reinforcing our commitment to strengthening our presence in the CNS therapeutic space and driving value creation in the U.S. generics market.

05/01/2026

We are pleased to share that Granules India Limited’s Gagillapur Unit has been certified as a Zero Waste to Landfill (ZWTL) facility through a third-party assessment, achieving a Platinum+ rating and diverting over 99% of waste from landfill.

This marks the first ZWTL-certified facility across Granules and is aligned with our broader sustainability commitment to achieve Zero Waste to Landfill across all facilities by 2030.

#

01/01/2026

As we step into the new year, Granules India extends its warm wishes to everyone.

We look forward to continuing our journey together, advancing healthcare with responsibility, trust, and purpose.

30/12/2025

Granules India Limited is pleased to share that our S&P Global ESG Score 2025 stands at 62/100, marking a clear improvement over last year. This reflects steady progress in strengthening our environmental, social, and governance disclosures, aligned with global best practices.

24/12/2025

Team Granules wishes you a Merry Christmas and a season filled with joy and good health

23/12/2025

Granules is proud to be recognized as a SEDEX Supplier Plus member for FY 26-27, achieving an impressive 86% ESG score. This places us among a select group of businesses leading in sustainable and ethical practices.

22/12/2025

A step forward in advancing our generics portfolio and patient-centric solutions.

Granules Pharmaceuticals, Inc., our US subsidiary, has received Tentative Approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Amphetamine Extended-Release Orally Disintegrating Tablets in multiple strengths 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, and 18.8 mg. It is the generic equivalent of ADZENYS XR-ODT®.

For more details, click here:
https://shorturl.at/4uuR7

19/12/2025

Metabolic health is a growing global challenge, and the pharmaceutical industry has a pivotal role to play.

Our Executive Director, Mrs. Uma Chigurupati, participated in the Gut & Metabolic Summit 2025, hosted by AIG Hospitals in Hyderabad, joining a panel on “Public–Private Collaboration to Tackle the Metabolic Crisis.”

She highlighted how the industry’s focus is shifting, “For decades, we concentrated on treating diseases after they occurred. With diabetes and obesity rising at alarming rates, this approach is no longer sustainable. The future lies in proactive health, predicting, preventing, and personalizing care before symptoms appear.”

Her insights reflect Granules India’s commitment to advancing healthcare, driving innovation, and partnering across ecosystems to address the metabolic health challenges at scale.

18/12/2025

We are pleased to announce that Granules India Limited has been recognized with the “Best CSR Initiative” Award for Breast Cancer Screening & Awareness in Rural Communities in the Year 2025 at the Indian Social Impact Awards 2025, an initiative by Indian CSR Awards held in New Delhi.

Our valued health partner, Dr Pragnya Chigurupati, Consultant Breast Oncologist at AIG Hospitals and Founder of UC Breast Foundation, who plays a pivotal role in driving our mission forward, accepted the award.

Since its launch over a year ago, Breast Health Express has conducted more than 50 camps, providing consultations to over 4,000 women across Telangana. We are committed to strengthening the fight against breast cancer and extending our reach to even more women in need.

Uma Chigurupati

17/12/2025

What a weekend to remember!

It was a privilege to be associated with Lionel Messi’s GOAT India Tour in Hyderabad and to see fans experience football greatness up close. The energy and excitement were truly unforgettable.

What was your favourite moment? Share it with us in the comments!

11/12/2025

Granules India Limited is proud to share that we have been placed on the “A” List in the 2025 CDP Climate Change Assessment, reflecting a two-level improvement from last year’s B rating. We have also secured a “B” in Water Security and a “B–” in Forests in our inaugural disclosure.

These ratings show the steady progress we are making toward our climate and nature goals. They reflect our efforts to build a stronger supply chain, support long-term business growth, and protect human health, all aligned with Our Purpose of “Healing Lives Responsibly through Pioneering Green Science.”

Our Chairman and Managing Director, Dr. Krishna Prasad Chigurupati, said “This year’s CDP ratings underline the momentum we have built in delivering climate outcomes, whether through our emission reductions, renewable energy adoption or responsible sourcing initiatives. We will continue to strengthen our environmental performance with science-based targets, transparent reporting, and sustained collaboration across our value chain.”

Learn more about our sustainability journey: https://lnkd.in/gf8C_Vg2

Address

Granules India Limited 15th Floor, Granules Tower, Botanical Garden Road, Kondapur
Hyderabad
500084

Opening Hours

Monday	9am - 6pm
Tuesday	9am - 6pm
Wednesday	9am - 6pm
Thursday	9am - 6pm
Friday	9am - 6pm

Telephone

+914069043500

Website

http://www.granulesindia.com/

Alerts

Be the first to know and let us send you an email when Granules India Limited posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Granules India Limited:

Shortcuts

Address
Telephone
Opening Hours
Alerts
Contact The Practice
Claim ownership or report listing

Want your practice to be the top-listed Clinic in Hyderabad?